About Acomplia (Rimonabant)
Acomplia (rimonabant) is an anti-obesity drug. Rimonabant acts on the brain of the patient, affecting the endocannabinoid system, which is responsible for regulating energy and appetite. The endocannabinoid system is the place that a great deal of cravings originate from, such as cravings for food, or cigarettes, or other pleasures. An overactive endocannabinoid system can sometimes trick people into thinking they are hungry and need to eat even when they are full. Generic Acomplia targets the endocannabinoid receptors and blocks them, reducing unwanted food cravings substantially.
Usage and Dose of Acomplia
- Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle.
- Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
- CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system). The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
A single course of Rimonabant usually lasts for two years, during which time the patient must monitor their diet and undertake an appropriate exercise plan. A visit to the doctor’s office is required for people who wish to begin taking generic Acomplia, as not all patients are good candidates for the drug, and taking such medication without medical supervision is dangerous to say the least.
A course of Rimonabant usually takes the form of a 20 mg pill at breakfast time. If a pill is missed, it can be taken later that day, but if it is missed entirely for a day it is inadvisable to ‘double up’ on this medication, as this can lead to increased side effects, or even illness.
Side Effects
Side effects in the trial on Acomplia in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.
Clinical studies found that 26 percent of people taking Acomplia reported psychiatric symptoms, including anxiety, insomnia, panic attacks as well as increases in aggression and agitation compared to patients given a placebo.
Acomplia has also been shown to cause increased suicidal tendencies and other depressive symptoms.
Buy Acomplia (Rimobant) at lowest prices online at Anabolic247.com
